24/7 Market News Snapshot 26 February, 2025 – AIM ImmunoTech Inc. (NYSE:AIM)

February 26, 2025

DENVER, Colo., 26 February, 2025 (247marketnews.com) – (NYSE:AIM) are discussed in this article.
AIM ImmunoTech Inc. has captured market attention today as its shares opened at $0.113 and have surged to $0.135, marking an approximate 8.96% increase since the previous session’s close at $0.124. This positive price action suggests a burgeoning bullish sentiment among investors, supported by a trading volume of 5.07 million shares, indicative of heightened interest and activity. Analysts are observing potential resistance levels at $0.135; if AIM maintains this upward trajectory, it could lead to further buying interest. Conversely, should the stock fall below $0.124, it may invoke caution among traders monitoring the investment’s stability.

In a strategic move to strengthen its leadership, AIM ImmunoTech has appointed David Chemerow as an Independent Director on its Board, effective immediately. With over 40 years of experience in finance, accounting, and operations, Mr. Chemerow’s expertise positions him as a valuable addition to the Company’s governance. His previous roles include serving as Chief Financial Officer and Treasurer at Comscore, Inc., and Chief Revenue Officer, showcasing his extensive background in media measurement and analytics.

Mr. Chemerow’s leadership experience extends to significant positions at Rentrak Corporation and various board memberships, including Dunham’s Athleisure Corporation and the Advisory Board of Huntington Outdoor, LLC. His philanthropic engagements highlight his commitment to community and the arts, underscoring a well-rounded professional profile.

William Mitchell, MD, PhD, Chairman of AIM’s Board, welcomed Mr. Chemerow, noting his leadership capabilities and financial insights as integral to AIM’s mission. Mr. Chemerow acknowledged the Company’s strong position within the immuno-pharma sector and the potential of its investigational drug Ampligen®. AIM ImmunoTech continues to focus on developing therapeutic solutions for various cancers, immune disorders, and viral diseases, and Mr. Chemerow’s appointment is expected to facilitate significant growth in its endeavors.

Related news for (AIM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.